TrialEvaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Trial details
- Registry ID
- NCT03180684
- Phase
- Phase 2
INO
Inovio Pharmaceuticals
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceREVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Trial details
- Registry ID
- NCT03185013
- Phase
- Phase 3
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Trial details
- Registry ID
- NCT03499795
- Phase
- Phase 2
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Trial details
- Registry ID
- NCT03721978
- Phase
- Phase 3
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Trial details
- Registry ID
- NCT04588428
- Phase
- Phase 2
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Trial details
- Registry ID
- NCT04642638
- Phase
- Phase 2, Phase 3
Latest recorded trial changes
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
NCT04588428 · Inovio Pharmaceuticals
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Frequency of Adverse Events in Part 1
Measure: Percentage of Participants with Adverse Events in Part 1
Measure: Frequency of Injection Site Reactions in Part 1
Measure: Percentage of Participants with Injection Site Reactions in Part 1
Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 1
Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1
Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1
Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1
Measure: Percentage Antigen Specific Cellular Immune Response in Part 1
Measure: Percentage of Seroconverted Participants in Part 1
Measure: Percentage of Participants with Overall Immune Response in Part 1
Measure: Frequency of Adverse Events in Part 2
Measure: Percentage of Participants with Adverse Events in Part 2
Measure: Frequency of Injection Site Reactions in Part 2
Measure: Percentage of Participants with Injection Site Reactions in Part 2
Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 2
Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2
Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2
Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2
Measure: Percentage Antigen Specific Cellular Immune Response in Part 2
Measure: Percentage of Seroconverted Participants in Part 2
Measure: Percentage of Participants with Overall Immune Response in Part 2
+ After
Measure: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs Measure: Part 1: Percentage of Participants With Injection Site Reactions Measure: Part 1: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 6 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 10 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 6 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 10 Measure: Part 2: Percentage of Participants With Adverse Events Measure: Part 2: Percentage of Participants With Injection Site Reactions Measure: Part 2: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 2: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody Measure: Part 2: Percentage Neutralizing Antibody Responders Measure: Part 2: Percentage of Antigen Specific Cellular Immune Responders